Volume Increase Versus Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success

Effect of Volume Increase Compared to Supplemental 4% Articaine Buccal Infiltration on Mepivacaine Inferior Alveolar Nerve Block Success in Cases With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05238727

Enrollment

Registered

2022-02-14

Start date

2022-03-31

Completion date

2023-09-30

Last updated

2022-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic Irreversible Pulpitis

Brief summary

To assess the anesthetic success of inferior alveolar nerve block (IANB), intraoperative pain intensity and need for supplemental anesthesia on administration of 1.8ml or 3.6ml 2% mepivacaine IANB, or 1.8ml 2% mepivacaine IANB plus 1.8ml 4% articaine buccal infiltration (BI) in mandibular molars with symptomatic irreversible pulpitis.

Detailed description

Patients with moderate-to-severe preoperative pain related to mandibular molars with symptomatic irreversible pulpitis will be included. Patients receive 1.8 ml, 3.6 ml 2% mepivacaine IANB, or 1.8ml 2% mepivacaine IANB plus 1.8ml 4% articaine BI. Anesthetic success of inferior alveolar nerve block, intraoperative pain intensity and need for supplemental anesthesia will be assessed during treatment.

Interventions

DRUG1.8 ml mepivacaine hydrochloride

1.8 ml mepivacaine IANB

DRUG3.6 ml mepivacaine hydrochloride

3.6 ml mepivacaine IANB

DRUG1.8 ml mepivacaine hydrochloride IANB plus 1.8 ml articaine hydrochloride BI

1.8 ml mepivacaine IANB plus 1.8 ml articaine BI

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

1. Patients in good health (ASA Class I, II). 2. Age between 18-60 years old. 3. Males or females. 4. Mandibular molar teeth diagnosed with symptomatic irreversible pulpitis. 5. Patients who can understand NRS scale and sign the informed consent.

Exclusion criteria

1. Patients who had used any type of analgesic medication during the preceding 8 hours before the treatment. 2. Pregnant or nursing females. 3. Patients with a contraindication for the use of mepivacaine, articaine or any used drug or material.

Design outcomes

Primary

Measure	Time frame	Description
Anesthetic success	During the treatment	Will be recorded by 11-point numerical rating scale (NRS) consisting of numbers from 0 through 10. 0: reading represents no pain 1-3 : readings represent mild pain 4-6 : readings represent moderate pain 7-10 : readings represent severe pain. Success will be defined as no to mild pain.

Secondary

Measure	Time frame	Description
Intraoperative pain	During the treatment	Will be recorded by 11-point numerical rating scale (NRS) consisting of numbers from 0 through 10. 0: reading represents no pain 1-3 : readings represent mild pain 4-6 : readings represent moderate pain 7-10 : readings represent severe pain.
Need for supplemental anesthesia	During the treatment	Whether the patient requires supplemental anesthesia or not

Contacts

Primary ContactReham Anwar Sleem

reham.anwar@dentistry.cu.edu.eg00201014110666

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026